Search In this Thesis
   Search In this Thesis  
العنوان
Adding Metformin to Insulin in controlling pregestational and gestational diabetes mellitus and improving neonatal outcome regarding birth weight
(A Randomized controlled trial)
/
المؤلف
Ahmed,Amr Saad Mahmoud .
هيئة الاعداد
باحث / عمرو سعد محمود أحمد
مشرف / أحمد رامي محمد رامي
مشرف / رحاب محمد عبد الرحمن
تاريخ النشر
2017.
عدد الصفحات
137.p;
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
أمراض النساء والتوليد
تاريخ الإجازة
1/1/2017
مكان الإجازة
جامعة عين شمس - كلية الطب - Obstetrics and Gynaecology
الفهرس
Only 14 pages are availabe for public view

from 137

from 137

Abstract

Abstract
Introduction: The proportion of pregnant women with gestational and pregestational diabetes mellitus (DM) is increasing, mainly from an increase in type 2 DM. Obesity, low level of physical activity,and, possibly, the exposure to diabetes in utero are major contributors to the increase in type 2 diabetes. Insulin has been the drug of choice for treating DM with pregnancy, because of its safety in pregnancy, lack of significant transplacental passage and long history of use. Aim of the work Aim:This study aims to prove benefits of adding metformin to insulin for controlling presentational and gestational diabetes mellitus and improving neonatal outcome. Patients and Methods The current study was conducted at Ain Shams university maternity hospital during the period between June 2016 to December 2016. Sixty-two pregnant women who fulfill the inclusion criteria were recruited. Summary: The proportion of pregnant women with gestational and pregestational diabetes mellitus (DM) is increasing, mainly from an increase in type 2 DM. Obesity, low level of physical activity, and, possibly, the exposure to diabetes in utero are major contributors to the increase in type 2 diabetes . Insulin has been the drug of choice for treating DM with pregnancy, because of its safety in pregnancy, lack of significant transplacental passage and long history of use. In the 21st century, oral hypoglycemic agents have been included in the armamentarium of treatment modalities for gestational diabetes mellitus (GDM). Earlier concerns with use of these agents in pregnancy were the unknown risk of teratogenicity and neonatal hypoglycemia caused by transplacental passage. Metformin is a biguanide that improves insulin sensitivity, probably by activating adenosine monophosphate (AMP) kinase. In contrast to insulin, metformin is not associated with weight gain or hypoglycemia. Reported outcomes of its use during pregnancy have been favorable.